Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
How to quickly read pharmaceutical company financial reports?
DrugDeal Decode
6 min read
How to quickly read pharmaceutical company financial reports?
28 August 2024
This article will use Pfizer as an example to teach you how to quickly learn to read Pharma/Biotech financial reports.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Aug 28
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Aug 28
28 August 2024
Aug 28th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
SIFI Gains European Commission Nod for AKANTIOR®
Latest Hotspot
4 min read
SIFI Gains European Commission Nod for AKANTIOR®
27 August 2024
SIFI revealed that the European Commission has granted approval for AKANTIOR® (polihexanide) for managing acanthamoeba keratitis (AK) in both adults and children aged 12 and over.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Aug 27
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Aug 27
27 August 2024
Aug 27th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
EU Commission Approves Celltrion’s SteQeyma®, a Stelara® Biosimilar, for Chronic Inflammatory Disorders
Latest Hotspot
3 min read
EU Commission Approves Celltrion’s SteQeyma®, a Stelara® Biosimilar, for Chronic Inflammatory Disorders
27 August 2024
The European Commission grants approval to Celltrion’s SteQeyma® (CT-P43), a biosimilar version of Stelara® (ustekinumab), for treating several chronic inflammatory disorders.
Read →
FDA Approves Galapagos' IND for Phase 1/2 Trial of GLPG5101, a CD19 CAR-T Therapy
Latest Hotspot
3 min read
FDA Approves Galapagos' IND for Phase 1/2 Trial of GLPG5101, a CD19 CAR-T Therapy
27 August 2024
Galapagos reveals FDA approval of its IND application for the Phase 1/2 ATALANTA-1 trial of CD19 CAR-T therapy, GLPG5101, in non-Hodgkin lymphoma that has relapsed or is refractory.
Read →
Moderna Gains European Commission Nod for RSV Vaccine mRESVIA(R)
Latest Hotspot
3 min read
Moderna Gains European Commission Nod for RSV Vaccine mRESVIA(R)
27 August 2024
Moderna, Inc. (NASDAQ:MRNA) reported that the European Commission (EC) has approved mRESVIA® (mRNA-1345), an mRNA vaccine targeting respiratory syncytial virus (RSV), for marketing.
Read →
Mabwell Receives CDE Nod for New Nectin-4 ADC, Set to Start Phase III Cervical Cancer Trial
Latest Hotspot
3 min read
Mabwell Receives CDE Nod for New Nectin-4 ADC, Set to Start Phase III Cervical Cancer Trial
27 August 2024
The company will commence a Phase III clinical trial aiming to investigate the effectiveness and safety of 9MW2821 in individuals with recurrent or metastatic cervical cancer (CC).
Read →
YolTech Therapeutics Initiates Clinical Trial with First Dose of YOLT-203 for In Vivo Gene Editing in PH1 Therapy
Latest Hotspot
4 min read
YolTech Therapeutics Initiates Clinical Trial with First Dose of YOLT-203 for In Vivo Gene Editing in PH1 Therapy
27 August 2024
YolTech Therapeutics Administers First Patient Dose of YOLT-203 in Clinical Trial for Groundbreaking In Vivo Gene Editing Therapy for PH1.
Read →
Accelerating mRNA Therapeutics Research: Harnessing Patsnap Bio for Efficient Nucleotide Sequence Retrieval and Patent Analysis
Bio Sequence
5 min read
Accelerating mRNA Therapeutics Research: Harnessing Patsnap Bio for Efficient Nucleotide Sequence Retrieval and Patent Analysis
27 August 2024
we will proceed with a specific sequence example to explore how nucleotide information can be efficiently retrieved using Patsnap Bio.
Read →
Pfizer and BioNTech get U.S. FDA approval for Omicron KP.2-adapted COVID-19 vaccine
Latest Hotspot
4 min read
Pfizer and BioNTech get U.S. FDA approval for Omicron KP.2-adapted COVID-19 vaccine
26 August 2024
FDA Approves Pfizer-BioNTech's Updated COVID-19 Vaccine for Ages 12 and Up; Grants Emergency Use for Ages 6 Months to 11 Years.
Read →
European Commission Approves BALVERSA® (Erdafitinib) for Advanced Urothelial Cancer
Latest Hotspot
4 min read
European Commission Approves BALVERSA® (Erdafitinib) for Advanced Urothelial Cancer
26 August 2024
The European Commission has granted approval for BALVERSA® (erdafitinib) in treating adults with advanced or metastatic urothelial cancer.
Read →